122567-95-7

Basic information

• Product Name: 1-(5-O-trityl-2-deoxy-β-D-threo-pentofuranosyl)-4-thiothymine
• Synonyms: 1-(5-O-trityl-2-deoxy-β-D-threo-pentofuranosyl)-4-thiothymine
• CAS NO: 122567-95-7
• Molecular Weight: 500.618
• Mol File: 122567-95-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1-(5-O-trityl-2-deoxy-β-D-threo-pentofuranosyl)-4-thiothymine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-O-trityl-2-deoxy-β-D-threo-pentofuranosyl)-4-thiothymine(122567-95-7)
• EPA Substance Registry System: 1-(5-O-trityl-2-deoxy-β-D-threo-pentofuranosyl)-4-thiothymine(122567-95-7)

Safety Data

• Hazardous Substances Data: 122567-95-7(Hazardous Substances Data)

Upstream product

• 1251063-59-8 4-thio-3'-O-(methylsulfonyl)-5'-O-trityl-2'-deoxythymidine 
• 35898-30-7 3',5'-di-O-benzoylthymidine 
• 7236-57-9 4-thiothymidine 
• 76-83-5 trityl chloride 

Downstream Products

• 122567-96-8 Methanesulfonic acid (2R,3R,5R)-5-(5-methyl-2-oxo-4-thioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2-trityloxymethyl-tetrahydro-furan-3-yl ester 

Relevant articles and documents

Antiviral activity of various 1-(2′-Deoxy-β- d -lyxofuranosyl), 1-(2′-Fluoro-β- d -xylofuranosyl), 1-(3′-Fluoro-β- d -arabinofuranosyl), and 2′-fluoro-2′,3′-didehydro-2′, 3′-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and human hepatitis B virus (HBV) replication

Despite the existence of successful vaccine and antiviral therapies, infection with hepatitis B virus (HBV) continues to be a major global cause of acute and chronic liver disease and high mortality. We synthesized and evaluated several lyxofuranosyl, 2′-fluoroxylofuranosyl, 3′- fluoroarabinofuranosyl, and 2′-fluoro-2′,3′-didehydro- 2′,3′-dideoxyribose pyrimidine nucleoside analogues for antiviral activities against hepatitis B virus. Among the compounds examined, 1-(2-deoxy-β-d-lyxofuranosyl)thymine (23), 1-(2-deoxy-β-d- lyxofuranosyl)-5-trifluoromethyluracil (25), 1-(2-deoxy-2-fluoro-β-d- xylofuranosyl)uracil (38), 1-(2-deoxy-2-fluoro-β-d-xylofuranosyl)thymine (39), 2′,3′-dideoxy-2′,3′-didehydro-2′- fluorothymidine (48), and 2′,3′-dideoxy-2′,3′-didehydro- 2′-fluoro-5-ethyluridine (49) were found to possess significant anti-HBV activity against DHBV in primary duck hepatocytes with EC50 values of 4.1, 3.3, 40.6, 3.8, 0.2, and 39.0 μM, respectively. Compounds 23, 25, 39, 48, and 49 (EC50 = 41.3, 33.7, 19.2, 2.0-4.1, and 39.0 μM, respectively) exhibited significant activity against wild-type human HBV in 2.2.15 cells. Intriguingly, 25, 39, 48, and 49 retained sensitivity against lamivudine-resistant HBV containing a single mutation (M204I) and 48 emerged as an effective inhibitor of drug-resistant HBV with an EC50 of 4.1 μM. In contrast, 50% inhibition could not be achieved by lamivudine at 44 μM concentration in the drug-resistant strain. The compounds investigated did not show cytotoxicity to host cells up to the highest concentrations tested.